HCAM, also referred to as CD44 antigen, is a cell‐surface glycoprotein that has been shown to be involved in cell adhesion, cellular interactions, and migration and was suggested as a potential diagnostic and prognostic marker of malignancy in breast and ovarian cancers.33, 34, 35 Our data show that the expression of HCAM was inhibited following PAK‐1 inhibition. This evidence concerns the gene CD44 and ovarian cancer.